[Improvement of allogeneic bone marrow transplantation and analysis of contributing factors].

H. Mitsui,Y. Ohsuga,M. Nakagawa,H. Teshima,T. Ueda,A. Hiraoka,H. Nakamura,H. Shibata,T. Masaoka,S. Ishigami

1987-11-01

Abstract:

What problem does this paper attempt to address?

Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response

Tiwadayo Braimoh,Esteban Burrone,Charles Gore,Pushpa Vijayaraghavan

DOI: https://doi.org/10.1186/s12992-024-01057-5

2024-07-02

Global Health

Abstract:During the COVID-19 pandemic, intellectual property licensing through bilateral agreements and the Medicines Patent Pool were used to facilitate access to new COVID-19 therapeutics in low- and middle-income countries (LMICs). The lessons learnt from the application of the model to COVID-19 could be relevant for preparedness and response to future pandemics and other health emergencies.The speed at which affordable versions of a new product are available in LMICs is key to the realization of the potential global impact of the product. When initiated early in the research and development life cycle, licensing could facilitate rapid development of generic versions of innovative products in LMICs during a pandemic. The pre-selection of qualified manufacturers, for instance building on the existing network of generic manufacturers engaged during the COVID-19 pandemic, the sharing of know-how and the quick provision of critical inputs such as reference listed drugs (RLDs) could also result in significant time saved. It is important to find a good balance between speed and quality. Necessary quality assurance terms need to be included in licensing agreements, and the potentials of the new World Health Organization Listed Authority mechanism could be explored to promote expedited regulatory reviews and timely access to safe and quality-assured products.The number, capacity, and geographical distribution of licensed companies and the transparency of licensing agreements have implications for the sufficiency of supply, affordability, and supply security. To foster competition and support supply security, licenses should be non-exclusive. There is also a need to put modalities in place to de-risk the development of critical pandemic therapeutics, particularly where generic product development is initiated before the innovator product is proven to be effective and approved. IP licensing and technology transfer can be effective tools to improve the diversification of manufacturing and need to be explored for regional manufacturing for accelerated access at scale in in LMICs and supply security in future pandemics.
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities

Sébastien Morin,Giulia Segafredo,Manuele Piccolis,Aditi Das,Meghmala Das,Nicola Loffredi,Amina Larbi,Kim Mwamelo,Elena Villanueva,Sandra Nobre,Esteban Burrone

DOI: https://doi.org/10.1016/S2214-109X(22)00460-0

Abstract:Biotherapeutics, such as recombinant proteins and monoclonal antibodies, have become mainstays of modern medicine as shown by their increasing number in the WHO Model List of Essential Medicines. However, despite frequently offering clinical advantages over standards of care, they remain largely out of reach for populations in low-income and middle-income countries (LMICs), partly because of high costs. Accordingly, the WHO Model List of Essential Medicines Expert Committee has requested that the Medicines Patent Pool explore intellectual property licensing to address this challenge. We therefore investigated how licensing could successfully improve affordability of and timely access to biotherapeutics in LMICs, by leveraging expert consultations, literature analysis, and internal technical knowledge. The key elements identified as relevant to support access to affordable biosimilars in LMICs through licensing include: prioritising potential biotherapeutic targets according to their potential for public health impact; supporting biosimilar product and clinical development (including through technology transfer to expedite regulatory approval); and facilitating biosimilars' entry and use in LMICs (by meeting procurement, supply chain, and health system requirements).
Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

Daniele Dionisio,Yunzhen Cao,Lu Hongzhou,Krisana Kraisintu,Daniela Messeri

DOI: https://doi.org/10.2174/157016206775197592

Abstract:Background: Threats by enforced Intellectual Property (IP) rights to equitable HIV treatment access by poor populations are impending. India and China's policy directions in the field will be crucial in ultimately affecting the affordability and accessibility of antiretroviral (ARV) therapy in the under-served markets. These directions, together with the exploitation level of IP-bound flexibilities and the evolutionary modelling in partnerships and trade agreements between research-based and generic pharmaceutical industry, will also affect the outcomes of self-sufficiency efforts now at their beginning in the developing world as far as domestic manufacturing of generic ARV drugs is concerned. Aims: This paper explores key issues, implications and interaction dynamics across these challenging scenarios while attempting to provide equitable solution glimpses into the near future. Results: Access-oriented long-term drug policy strategies entitled to pass muster of governments, research-based as well as generic industries in both developed and developing countries are needed if equitable access to affordable ARV treatments by poor people has to be achieved despite enforced IP rights. Predictable dynamics between western multinationals and transitional country generic corporations let regard IP-bound Voluntary License flexibilities as a fitting measure into just mentioned needs especially if substantial incentives to generic corporations are concurrently secured. Efforts to equitably expand ARV drug access through exploiting IP opportunities should encompass attainment of self-sufficiency in domestic drug manufacturing whenever basic requirements are in place in the developing world as a whole. A credible industrial potential would act, indeed, as a boosting factor for drawing branded drug producers into technology transfer agreements, the terms of which would let all contractors enjoy substantial advantages. These perspectives consistently bind up with the foreseeable long-term trade and drug policy directions of India and China according to frontier crossing implications of their key IP management trends as well as their multifaceted penetration strategies of both the wealthy and under-served markets worldwide. As coherent with these perspectives, more disbursement by wealthy country governments and donors to basic infrastructure development in sub-Saharan African nations with stable governments in place is urged both as a priority for improving Africa's economy and a prerequisite for allowing domestic industrial plants to take off. Aiming at the targets just underscored, WHO's brokering role in negotiated agreements between wealthy and developing country-based firms as well as its technical guidance in setting international standards have always to be sought if equitable and appropriate end results are to be attained. Conclusion: Overall insights in this paper would mean that, while research-based corporations are to be praised whenever waiving, on humanitarian purposes, part of their profits, the trade and profit rules cannot basically be given up if long-term sustainable results are the goal to look for. Only negotiated agreements securing all contracting parties lasting advantages may ensure shifting of such a goal from mere vision to a really sustainable attainment.
TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

Shiri Mermelstein,Hilde Stevens

DOI: https://doi.org/10.3390/pharmaceutics14010048

IF: 6.525

2021-12-27

Pharmaceutics

Abstract:Governed through the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) since 1995, the current medical R&D system requires significant trade-offs between innovation and high monopoly prices for patented drugs that restrict patient access to medicines. Since its implementation, few amendments have been made to the original TRIPS agreement to allow low- and middle-income countries (LMICs) to facilitate access by generic manufacturers through flexible provisions, such as compulsory licensing and parallel import. Although a useful policy tool in theory, the routine use of TRIPS flexibilities in LMICs in the procurement of new essential medicines (EMs) is regarded as a ‘last resort’ due to strong political response in high-income countries (HICs) and new trade agreements’ restrictions. In this context, access-oriented biomedical Public-Private Partnerships (PPPs) have emerged. More recently, leading multilateral health organizations have recommended different types of intellectual property (IP) interventions, voluntary biomedical patent pools, as strategies to reduce prices and increase the diffusion of novel EMs in LMICs. Nevertheless, the recent Ebola and COVID-19 outbreaks highlight growing concerns regarding the use of TRIPS flexibilities and the limited success of voluntary mechanisms in promoting access to medicines in the Global South amidst health crises. This review aims at describing the state-of-the-art empirical research on IP-related options and voluntary mechanisms applied by emerging PPPs to guarantee timely and affordable access to EM in LMICs and reflect on both models as access paradigms. Some suggestions are put forward for future research paths on the basis of these analyses and in response to contemporary debates on waiving key IP rights on COVID-19 therapies, diagnostics, and vaccines.

pharmacology & pharmacy
The long wait for long-acting HIV prevention and treatment formulations

Willem Daniel Francois Venter,Monica Gandhi,Simiso Sokhela,Kenly Sikwese,Helen Bygrave,Louis Da Gama,Ndiviwe Mphothulo,Lise Jamieson,Mark J Siedner,Anton Pozniak,Pablo Rojo,Solange L Baptiste,Jacque Wambui,Gesine Meyer-Rath,Brian Honerman,Mitchell Warren,Linda Gayle-Bekker,Phumla Sinxadi,Simon Collins,Jessica Burry,Karlien Möller,Polly Clayden,Andrew Owen,Andrew Hill

DOI: https://doi.org/10.1016/S2352-3018(24)00173-5

2024-08-16

Abstract:Large randomised studies of new long-acting medications for the prevention and treatment of HIV have shown high effectiveness and acceptability. Although modelling studies indicate these agents could be fundamental in HIV elimination, coordination of their entry into health-care markets is crucial, especially in low-income and middle-income countries with high HIV prevalence, where coordination is low despite UNAIDS flagging that global HIV targets will not be met. Research and implementation projects are tightly controlled by originator pharmaceutical companies, with only a small percentage of eligible people living with or affected by HIV benefiting from these projects. WHO, financial donors, manufacturers, and governments need to consider urgent coordinated action from stakeholders worldwide, akin to the successful introduction of dolutegravir into treatment programmes across low-income and middle-income countries. Without this immediate coordination, large-scale access to long-acting agents for HIV will be delayed, potentially extending into the 2030s. This delay is unacceptable considering the established global HIV targets.
Impact of long-acting therapies on the global HIV epidemic

Nomathemba C. Chandiwana,Celicia M. Serenata,Andrew Owen,Steve Rannard,Carmen Pérez Casas,Cherise Scott,Andrew Hill,Polly Clayden,Charles Flexner,Nomathemba C. Chandiwana,Celicia M. Serenata,Andrew Owen,Steve Rannard,Carmen Pérez Casas,Cherise Scott,Andrew Hill,Polly Clayden,Charles Flexner

DOI: https://doi.org/10.1097/qad.0000000000003102

IF: 4.632

2021-12-15

AIDS

Abstract:Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current daily-based oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.

immunology,infectious diseases,virology
Orbital complications of functional endoscopic sinus surgery: MR and CT findings.

M. T. Bhatti,I. Schmalfuss,A. Mancuso

DOI: https://doi.org/10.1016/J.CRAD.2005.03.005

IF: 3.389

2005-08-01

Clinical Radiology

Abstract:
Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project

Nadia Nguyen,Benjamin Lane,Sarit A Golub,Cody Chastain,Jason Zucker,Katherine King,Marvell Terry 2nd,Jennifer Burdge,Caroline Carnevale,Anahit Muscarella,Delivette Castor,Bryan Kutner,Kathrine Meyers

DOI: https://doi.org/10.1002/jia2.26282

Abstract:Introduction: Approval of the first long-acting injectable antiretroviral therapy (LAI ART) medication heralded a new era of HIV treatment. However, the years since approval have been marked by implementation challenges. The "Accelerating Implementation of Multilevel Strategies to Advance Long-Acting Injectable for Underserved Populations (ALAI UP Project)" aims to accelerate the systematic and equitable delivery of LAI ART. Methods: We coded and analysed implementation barriers according to the Consolidated Framework for Implementation Research (CFIR) domains, desired resources and programme goals from questionnaire short-answer responses by clinics across the United States responding to ALAI UP's solicitation to participate in the project between November 2022 and January 2023. Results: Thirty-eight clinics responded to ALAI UP's solicitation. The characteristics of LAI ART as an innovation (cost, complexity of procurement, dosing interval, limited eligibility) precipitated and interacted with barriers in other CFIR domains. Barriers included obtaining coverage for the cost of medication (27/38 clinics) (outer setting); need for new workflows and staffing (12/38) and/or systems to support injection scheduling/coordination (16/38), transportation and expanded clinic hours (13/38) (inner setting); and patient (10/38) and provider (7/38) education (individuals). To support implementation, applicants sought: technical assistance to develop protocols and workflows (18/38), specifically strategies to address payor challenges (8/38); additional staff for care coordination and benefits navigation (17/38); opportunities to share experiences with other implementing clinics (12/38); patient-facing materials to educate and increase demand (7/38); and support engaging communities (6/38). Clinics' LAI ART programme goals varied. Most prioritized delivering LAI ART to their most marginalized patients struggling to achieve viral suppression on oral therapy, despite awareness that current US Food and Drug Administration approval is only for virally suppressed patients. The goal for LAI ART reach after 1 year of implementation ranged from ≤10% of patients with HIV on LAI ART (17/38) to ≥50% of patients (2/38). Conclusions: Diverse clinic types are interested in offering LAI ART and most aspire to use LAI ART to support their most vulnerable patients sustain viral suppression. Dedicated resources centred on equity and relevant to context and population are needed to support implementation. Otherwise, the introduction of LAI ART risks exacerbating, not ameliorating, health disparities.
Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements

Ed J Griffen,Pascale Boulet,ASAP Discovery Center,COVID Moonshot

DOI: https://doi.org/10.12688/wellcomeopenres.22645.1

2024-07-15

Abstract:The COVID-19 pandemic demonstrated that the current purely market-driven approaches to drug discovery and development alone are insufficient to drive equitable access to new therapies either in preparation for, or in response to, pandemics. A new global framework driven by equity is under negotiation at the World Health Organization to support pandemic preparedness and response. Some believe that the global intellectual property (IP) system itself is part of the problem and propose a purely Open Science approach. In this article, we discuss how existing IP frameworks and contractual agreements may be used to create rights and obligations to generate a more effective global response in future, drawing on experience gained in the COVID Moonshot program, a purely Open Science collaboration, and the ASAP AViDD drug discovery consortium, which uses a hybrid, phased model of Open Science, patent filing and contractual agreements. We conclude that 'straight to generic' drug discovery is appropriate in some domains, and that targeted patent protection, coupled with open licensing, can offer a route to generating affordable and equitable access for therapy areas where market forces have failed. The Extended Data contains a copy of our model IP policy, which can be used as a template by other discovery efforts seeking to ensure their drug candidates can be developed for globally equitable and affordable access.
Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States

Tara McCrimmon,Lauren F. Collins,Amaya Perez-Brumer,Angela R. Bazzi,Victoria A. Shaffer,Deanna Kerrigan,Maria L. Alcaide,Morgan M. Philbin

DOI: https://doi.org/10.1089/apc.2023.0248

IF: 5.944

2024-02-22

AIDS Patient Care and STDs

Abstract:Long-acting injectable antiretroviral therapy (LAI ART) has the potential to address adherence obstacles associated with daily oral ART, leading to enhanced treatment uptake, adherence, and viral suppression among people living with HIV (PLWH). Yet, its potential may be limited due to ongoing disparities in availability and accessibility. We need a better understanding of the organizational context surrounding the implementation of LAI ART, and to inform its widespread rollout, we conducted 38 in-depth interviews with medical and social service providers who offer HIV care at private and hospital-based clinics across six US cities. Our findings highlight real-world implementation barriers outside of clinical trial settings. Providers described ongoing and anticipated barriers across three stages of LAI ART implementation: (1) Patient enrollment (challenges registering patients and limited insurance coverage), (2) medication delivery (insufficient personnel and resources), and (3) leadership and management (lack of interprofessional coordination and a lack of programming guidelines). Providers described how these barriers would have a disproportionate impact on under-resourced clinics, potentially exacerbating existing disparities in LAI ART access and adherence. Our findings suggest strategies that clinic leadership, policymakers, and other stakeholders can pursue to promote rapid and equitable LAI ART implementation in clinics across the United States. Resource and staffing investments could support clinics to begin, sustain, and scale up LAI ART delivery; additionally, the establishment of guidelines and tools could facilitate wider adoption of LAI ART across clinical settings. These efforts are crucial to promote resourced, standardized, and equitable implementation of LAI ART and maximize its potential to help end the HIV epidemic.

infectious diseases,public, environmental & occupational health
Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia

Benjamin R. Bavinton,Heather-Marie A. Schmidt,Stephen Mills,Nittaya Phanuphak

DOI: https://doi.org/10.1071/sh23192

2024-06-08

Sexual Health

Abstract:Long-acting injectable PrEP, particularly cabotegravir (CAB-LA), has the potential to enhance HIV prevention in Asia, and was the topic of a roundtable held in Singapore in June 2023. Despite proven efficacy, CAB-LA's impact in Asia is hindered by regulatory, manufacturing, and cost barriers. There is an urgent need to address these challenges to expedite CAB-LA's introduction and scale-up, including collaborative research, streamlined regulatory processes, and increased manufacturing capacity. We call for better preparedness in long-acting PrEP in research and implementation science, product licensing and accessibility, and capacity readiness for scale-up, to meet the significant demand among key populations in Asia.

infectious diseases,public, environmental & occupational health
The Global Health Licensing Program: A New Model for Humanitarian Licensing at the University Level

Beirne Roose-Snyder,Megan K. Doyle

DOI: https://doi.org/10.1177/009885880903500203

2009-06-01

Abstract:Disparities in health outcomes and access to the essential medicines that affect health outcomes are two of the most pressing issues facing the world today. The lack of adequate health care in developing countries is rooted in a number of systemic problems, including insufficient health infrastructure, lack of medical personnel, government corruption and incompetence, and the high price of pharmaceuticals. These problems are not mutually exclusive. Instead, they are mutually reinforcing, particularly in least developed and developing countries. The high cost of drugs and vaccines is undoubtedly one of the driving forces in disparate health outcomes, and partial solutions to poor health in the developing world rightly focus on lowering the cost of health products, while preserving the financial incentive for innovation. The high cost of many medicines is largely due to the international patent system, codified by the Trade Related Intellectual Property Rights (TRIPS) Agreement, which grants a monopoly to the innovator and allows it to completely control pricing for a period of years. The result is an access gap, whereby patients in low- and middle-income countries (LMI) cannot afford expensive patented drugs, while patients in wealthy countries can afford and do have access to such treatments.
[Anemia due to anerythroblastosis (Blackfan-Diamond type) in a child with constitutional chromosomal abnormalities].

C. Brizard,C. Fayard,J. Fraisse,J. L. le Petit,B. Gannat,Y. Hermouet

1971-04-01

Abstract:
Challenges for novel antiretroviral development in an era of widespread TLD availability

Cassandra Fairhead,Jacob Levi,Andrew Hill

DOI: https://doi.org/10.1093/cid/ciae361

IF: 20.999

2024-07-13

Clinical Infectious Diseases

Abstract:Over 80% of people living with HIV in low-and-middle-income countries (LMICs) take first-line TDF/XTC/DTG (TLD). Due to hard-fought activism, in >100 LMICs TLD now costs under $45pppy under Voluntary License. With final DTG patents expiring by 2029, generic TLD will soon be available globally. We identify seven critical benchmarks underpinning TLDs success which novel ART should now meet, and an eighth for which novel ART should aim. These are superior efficacy; a high genetic barrier to resistance; safety in hepatitis B coinfection; favourable drug-drug interaction profiles including with antimycobacterials; efficacy in HIV-2; safety in pregnancy, long-acting formulation availability and affordable pricing from the outset. We illustrate when generic TLD will become available worldwide and compare this with trial programmes and approval timelines for two case-study novel ART combinations: islatravir/doravirine and cabotegravir/rilpivirine. We demonstrate that currently these regimens and trial programmes will not meet key benchmarks required to compete with TLD.

immunology,infectious diseases,microbiology
The Role of Intellectual Property Rights and Access to Medical Products in the WHO African Region: 25 Years After the Trips Agreement

Marion Motari,Jean-Baptiste Nikiema,Ossy Muganga Julius Kasilo,Stanislav Kniazkov,Andre Loua,Aissatou Sougou,Prosper Tumusiime

DOI: https://doi.org/10.21203/rs.3.rs-62959/v1

2020-09-10

Abstract:Abstract BackgroundIt is now 25 years since the adoption of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the same concerns raised during its negotiations such as high prices of medical products, market exclusivity and delayed market entry for generics remain relevant as highlighted recently by Ebola and COVID-19 pandemics. The World Health Organization’s mandate to work on the interface between intellectual property, innovation and access to medicine has been continually reinforced and extended to include providing support to countries on the implementation of TRIPS flexibilities in collaboration with stakeholders. This study analyses the role of intellectual property on innovation and access to medical products in the African Region. Methods:We analyze patent data from the African Regional Intellectual Property Organization (ARIPO) and Organisation Africaine de la Propriété Intellectuelle (OAPI) to show trends and to identify the main diseases covered and how they correspond with top causes of morbidity and mortality. We also review legislation to assess how TRIPS flexibilities are implemented in countries.ResultsPatenting was low for African countries. Only South Africa and Cameroon appeared in the list of top ten originator countries for ARIPO and OAPI respectively. Main diseases covered by African patents were HIV/AIDS, cardiovascular diseases, cancers and tumors. 39 countries have applied TRIPS flexibilities, with the most common being compulsory licensing and LDC transition provisions. A third of the compulsory licensing application were not executed following voluntary licensing agreements. No country had legislated on research and regulatory review exceptions and patent term extension.DiscussionThere’s modest alignment between innovation and health challenges. Compulsory licensing applications may have served to encourage voluntary licensing arrangements. Countries have enacted laws that allow them to deploy TRIPS flexibilities for public health needs. ConclusionsThere’s need to develop and strengthen health innovation systems in the region. Opportunities exist for WHO to work with ARIPO and OAPI to support countries in reviewing their legislation to be more responsive to public health needs.
Developmental role of PTHrP in murine molars.

J. Liu,M. Tabata,K. Yamashita,T. Matsumura,M. Iwamoto,K. Kurisu

DOI: https://doi.org/10.1111/J.1600-0722.1998.TB02167.X

European Journal Of Oral Sciences

Abstract:Although PTHrP is produced in multiple fetal tissues, its precise physiological functions have yet to be clearly elucidated. The present study was undertaken to elucidate the biological role of PTHrP in the development of tooth. In rat tooth germs, the PTHrP and its receptor genes were expressed in the enamel organ and dental mesenchyme, respectively. When mouse tooth explants were cultured with antisense oligodeoxyribonucleotides (ODN) against mouse PTHrP mRNA in serum-free medium, an invasion of bone tissue was observed in the tooth germs. On the other hand, the explants cultured without ODN or with sense ODN showed normal histological structures similar to those observed in vivo. These results suggest that PTHrP is essential for tooth development and for the protection of tooth germs from the invasion of bone tissue.
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries

Shelly Malhotra,Anne-Isabelle Cameron,Dzintars Gotham,Esteban Burrone,Peter J Gardner,Colleen Loynachan,Sébastien Morin,Cherise P Scott,Carmen Pérez-Casas

DOI: https://doi.org/10.1371/journal.pgph.0003418

2024-07-01

Abstract:Monoclonal antibodies (mAbs) are revolutionizing management of non-communicable diseases in high-income countries and are increasingly being advanced for a range of infectious diseases (IDs). However, access to existing mAbs is limited in low- and middle-income countries (LMICs), and investment in developing fit-for-purpose mAbs for IDs that disproportionately affect LMICs has been limited. Underlying these access barriers are systemic challenges, including a lack of commercial incentives to target LMIC markets and complexity in manufacturing and regulatory processes. Novel strategies are needed to overcome systemic access barriers for mAbs. We outline key areas where new approaches could address these barriers, based on a multistakeholder consultation in March 2023. Three disease-market archetypes are identified to guide thinking about business models tailored to different contexts. New business models are needed to incentivize development and manufacturing of ID mAbs and to ensure mAbs are optimized with a target product profile and cost of goods that enable use in diverse LMIC settings. Lessons can be applied from voluntary licensing strategies and product development partnerships that have shown success in catalysing development and affordable supply for a range of infectious diseases. Technology transfer will be key to expand LMIC research and manufacturing capacity and to enable sustainable and diversified supply. Improved market intelligence, demand aggregation mechanisms, and portfolio-based manufacturing models could be used to de-risk commercial investment and establish a sustainable manufacturing ecosystem for affordable mAbs. Novel regulatory approaches and robust technology transfer may reduce data requirements and timelines for biosimilar approvals. Trailblazer products, with coordinated "end-to-end" support from funders, can demonstrate proof of concept for pathways to accessible mAbs across a broader range of LMICs. Research funders; local, regional, global health agencies; and, private sector partners should commit to implementing innovative partnerships and end-to-end strategies that enable equitable access to mAbs for infectious diseases in LMICs.
Global regulatory reforms to promote equitable vaccine access in the next pandemic

Richard Mahoney,Peter J Hotez,Maria Elena Bottazzi

DOI: https://doi.org/10.1371/journal.pgph.0002482

2023-10-18

Abstract:There is broad consensus that the global response to the Covid-19 pandemic was inadequate, leading to unacceptable levels of avoidable morbidity and mortality. Three strategic missteps led to the lack of equitable vaccine access: The heavy reliance on commercial vaccine manufacturers in high-income countries (HICs) versus low- and middle-income countries (LMICs); the emergence of vaccine nationalism restricting and delaying the supply of vaccines to LMICs; and an inadequate support or recognition for LMIC national regulatory authorities. To avoid these inequities in a future pandemic, we focus on three successful vaccine development and technology transfer case studies-the Hepatitis B vaccine produced in South Korea in the 1980s; the Meningitis A vaccine for Africa led by Program for Appropriate Technologies in Health (PATH) and the World Health Organization (WHO) in the 2000s; and a recombinant SARS CoV-2 protein-based vaccine technology from the Texas Children's Hospital transferred to India and to Indonesia. In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of the WHO Prequalification (PQ) system to ensure early vaccine availability in LMICs especially during pandemics. Advancing LMIC National Regulatory Authorities (NRAs) to Stringent Regulatory Authorities (SRAs) status will require substantial resources, but the benefits for future pandemic control and for health in LMIC would be immense. We call on the WHO, United Nation (UN) agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators to achieve stringent status by 2030.
Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries

Owen Dyer

DOI: https://doi.org/10.1136/bmj.q2200

2024-10-08

BMJ

Abstract:Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing HIV infection, in 120 countries for a fraction of its current price.The company's announcement has been eagerly anticipated since July, when the twice yearly injectable antiviral showed groundbreaking results in its first trial in HIV prevention. That study, among adolescent girls and young women in South Africa and Uganda, found no new infections in the lenacapavir arm (0 per 100 person years, 95% confidence interval 0.00 to 0.19), far outperforming existing oral pre-exposure prophylaxis (PrEP) drugs.1Gilead will provide royalty free licences to three Indian generics makers, Dr Reddy's Laboratories, Emcure Pharmaceuticals, and Hetero Laboratories, as well as to Ferozsons Laboratories in Pakistan, Eva Pharma in Egypt, and to US based Mylan.Until those generic makers' production is fully underway, Gilead will provide them...

medicine, general & internal
Long‐acting injectable cabotegravir for PrEP: A game‐changer in HIV prevention?

Geoffroy Liegeon,Jade Ghosn

DOI: https://doi.org/10.1111/hiv.13451

2022-12-07

HIV Medicine

Abstract:Background Long‐acting injectable cabotegravir (CAB‐LA) represents a new additional option for HIV prevention in people at substantial risk of HIV infection that may fill the gaps in pre‐exposure prophylaxis (PrEP) uptake, adherence, and retention in users having difficulty with oral PrEP. Data from clinical trials demonstrated that CAB‐LA was safe, highly effective, and well‐accepted for HIV prevention. However, the occurrence of breakthrough HIV infections despite timely injections, HIV seroconversion timing and patterns, risk of selection and dissemination of resistance‐associated mutations to integrase inhibitors, complexity of follow‐up, logistical considerations, and its cost effectiveness compared with oral PrEP constitute significant issues for the integration of CAB‐LA into clinical routine. Findings These concerns need to be addressed before moving forward with large‐scale implementation programmes. Pilot and implementation projects are required in the following areas: HIV testing algorithms, patient education, clinic procedures, protocols for switching and discontinuation, efficacy and safety in populations not included in clinical trials, and demedicalization processes. The development of models to increase the uptake of, adherence to, and persistence with and after CAB‐LA injections will also be of paramount importance for success. Lessons learned from these projects will increase experience, staff expertise, and organizational and training capacities to support the roll‐out of this new agent as part of HIV prevention programmes. Conclusion CAB‐LA has not yet achieved its full potential in HIV prevention, and strong commitment from all stakeholders is required to push CAB‐LA as a game‐changer in HIV response.

infectious diseases

[Improvement of allogeneic bone marrow transplantation and analysis of contributing factors].

Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response

Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

The long wait for long-acting HIV prevention and treatment formulations

Impact of long-acting therapies on the global HIV epidemic

Orbital complications of functional endoscopic sinus surgery: MR and CT findings.

Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project

Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements

Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States

Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia

The Global Health Licensing Program: A New Model for Humanitarian Licensing at the University Level

[Anemia due to anerythroblastosis (Blackfan-Diamond type) in a child with constitutional chromosomal abnormalities].

Challenges for novel antiretroviral development in an era of widespread TLD availability

The Role of Intellectual Property Rights and Access to Medical Products in the WHO African Region: 25 Years After the Trips Agreement

Developmental role of PTHrP in murine molars.

Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries

Global regulatory reforms to promote equitable vaccine access in the next pandemic

Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries

Long‐acting injectable cabotegravir for PrEP: A game‐changer in HIV prevention?